Qsemble Capital Management LP Invests $311,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Qsemble Capital Management LP bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,489 shares of the biotechnology company’s stock, valued at approximately $311,000.

Other large investors also recently modified their holdings of the company. Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $31,000. New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics during the first quarter worth approximately $32,000. Nkcfo LLC acquired a new position in Sarepta Therapeutics in the second quarter valued at approximately $43,000. Huntington National Bank lifted its holdings in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the period. Finally, Riggs Asset Managment Co. Inc. lifted its holdings in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Up 5.7 %

Sarepta Therapeutics stock opened at $137.94 on Thursday. The company has a market cap of $13.18 billion, a P/E ratio of 110.35 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1-year low of $78.67 and a 1-year high of $173.25. The company has a fifty day simple moving average of $121.90 and a 200 day simple moving average of $131.39. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Robert W. Baird cut their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. HC Wainwright assumed coverage on shares of Sarepta Therapeutics in a report on Monday. They issued a “sell” rating and a $80.00 price objective on the stock. Evercore ISI cut their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Finally, William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $175.77.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.